Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun An
experimental drug being developed to treatParkinson's disease psychosis andschizophrenia .
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word pimavanserin.
Examples
-
ACADIA is developing a portfolio consisting of four product candidates including pimavanserin, which is being developed for three separate neurological and psychiatric indications in collaboration with Biovail.
-
"The first half of 2010 was focused on executing our broad development strategy designed to leverage the potential of pimavanserin over a range of neurological and psychiatric indications with large unmet medical needs together with our collaborative partner, Biovail," said Uli Hacksell, Ph. D.,
-
Biovail provides update on its Phase III program with pimavanserin for Parkinson's disease psychosis
THE MEDICAL NEWS Editors 2010
-
Biovail Corporation today provided an update on its Phase III program with pimavanserin for Parkinso ...
THE MEDICAL NEWS Editors 2010
-
Biovail Corporation today provided an update on its Phase III program with pimavanserin for Parkinso ...
THE MEDICAL NEWS Editors 2010
-
The decrease in external service costs was primarily attributable to lower clinical costs incurred on ACADIA's Phase III program with pimavanserin for
-
"The first half of 2010 was focused on executing our broad development strategy designed to leverage the potential of pimavanserin over a range of neurological and psychiatric indications with large unmet medical needs together with our collaborative partner, Biovail"
-
Included in this amount, is a portion of the expenses associated with the new Phase 3 trials for pimavanserin in (1) Parkinson's disease pyschosis, which is expected to begin in the second quarter of 2010 and to cost a total of $10 million to $15 million, and (2) in schizophrenia, as adjunct therapy, which is expected to begin mid-2010 and to cost a total of $30 million to $40 million.
THE MEDICAL NEWS Editors 2010
-
In addition to pimavanserin, ACADIA has a product candidate in Phase II development for chronic pain and a product candidate in Phase I development for glaucoma, both in collaboration with Allergan, as well as a product candidate in IND-track development for schizophrenia in collaboration with Meiji Seika Kaisha.
-
Biovail provides update on its Phase III program with pimavanserin for Parkinson's disease psychosis
THE MEDICAL NEWS Editors 2010
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.